Cargando…

The Combination of Dupilumab with Other Monoclonal Antibodies

INTRODUCTION: Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD), which could be associated with atopic and non-atopic comorbidities for which concomitant administration of targeted pharmacotherapy including monoclo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gisondi, P., Maurelli, M., Costanzo, A., Esposito, M., Girolomoni, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823163/ https://www.ncbi.nlm.nih.gov/pubmed/36355314 http://dx.doi.org/10.1007/s13555-022-00851-6

Ejemplares similares

Advanced Glycation End Products and Psoriasis
por: Maurelli, Martina, et al.
Publicado: (2023)

Uncommon Non-Infectious Annular Dermatoses
por: Maurelli, Martina, et al.
Publicado: (2022)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Bellinato, Francesco, et al.
Publicado: (2021)

Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature
por: Maurelli, Martina, et al.
Publicado: (2021)

Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab
por: Bellinato, Francesco, et al.
Publicado: (2023)

Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature
por: Bellinato, Francesco, et al.
Publicado: (2021)

Advanced Glycation End Products in the Pathogenesis of Psoriasis
por: Papagrigoraki, Anastasia, et al.
Publicado: (2017)

Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
por: Ying, Yang, et al.
Publicado: (2021)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Pruritus as a Distinctive Feature of Type 2 Inflammation
por: Garcovich, Simone, et al.
Publicado: (2021)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Treatment of Refractory Prurigo Nodularis with a Monoclonal Antibody Dupilumab with Surprising Clinical Response
por: Alves, Juliana P., et al.
Publicado: (2023)

Developing Monoclonal Antibodies for Immunohistochemistry
por: Cordell, Jacqueline
Publicado: (2022)

How Can Dupilumab Cause Eosinophilic Pneumonia?
por: Kurihara, Momoko, et al.
Publicado: (2022)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Monoclonal Antibodies and Flaviviruses: a Possible Option?
por: Mancini, Nicasio
Publicado: (2022)

Future of Monoclonal Antibody Therapy in Parkinson’s Disease
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2022)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Immunocytochemical Labelling of Haematological Samples Using Monoclonal Antibodies
por: Erber, Wendy N.
Publicado: (2021)

Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
por: Eccles, Suzanne A
Publicado: (2001)

Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report
por: Shimodaira, Yosuke, et al.
Publicado: (2021)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
por: Jalalizadeh, Mehrsa, et al.
Publicado: (2023)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
por: Musto, Pellegrino
Publicado: (2018)

The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)
por: Hardison, Scott A., et al.
Publicado: (2023)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Updates for Health Providers on Monoclonal Antibodies for COVID-19: Less Promising Adjunct and Never an Alternative to Vaccinations
por: Berges, Maja, et al.
Publicado: (2022)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Clinical Characteristics of Patients with Pustular Psoriasis: A Single-Center Retrospective Observational Study
por: Gisondi, Paolo, et al.
Publicado: (2022)

Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks
por: Gisondi, Paolo, et al.
Publicado: (2020)

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules
por: Bellinato, Francesco, et al.
Publicado: (2021)

Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies
por: Bellinato, F., et al.
Publicado: (2022)

Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre
por: Napolitano, Maddalena, et al.
Publicado: (2021)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0ua0gm4ifqjuv2gphits3pqcf6